Targeted therapy for triple-negative breast cancer: Where are we?

Authors

  • Michael J. Duffy,

    Corresponding author
    1. UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin, Ireland
    2. UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    • UCD Clinical Research Centre, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland
    Search for more papers by this author
    • Tel.: 353-1-7165814, Fax: 353-1-2214428

  • Patricia M. McGowan,

    1. UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Search for more papers by this author
  • John Crown

    1. National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
    2. Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland
    Search for more papers by this author

Abstract

Breast cancers that are negative for estrogen receptor (ER), progesterone receptors (PR) and HER2, using standard clinical assays, have been dubbed triple-negative (TN). Unlike other molecular subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer. Preclinical studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2). Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer. The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.

Ancillary